Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 August 2021Published: 26 March 2008
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 September 2020
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for previously treated severe nasal polyps [ID1659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC